Lilly Delivers Strong Third-Quart...(rowth in the U.S. benefitedfrom the rece...),Health

Year-to-Date Results

For the first nine months of 2007, worldwide reported sales increased 17 percent, to $13.444 billion, compared with sales for the same period in 2006. Reported net income and earnings per share were $2.099 billion and $1.93, respectively. Results for the first nine months of 2007 were affected by the acquisitions of ICOS, Hypnion Inc., and Ivy Animal Health, Inc., as well as the other items noted in the table below.

For the first nine months of 2007, worldwide pro forma sales increased 13 percent to $13.517 billion, compared with the first nine months of 2006. As a result of sales growing faster than cost of sales and operating expenses, pro forma adjusted net income and earnings per share grew 20 percent and 19 percent, to $2.877 billion and $2.64, respectively. The pro forma reconciliation of year-to-date earnings per share for 2007 is shown in the table below.

Earnings per Share Reconciliation

----------------------------------

Year-to-date % Growth

------------ --------

2007 2006

---- ----

E.P.S. (reported) $1.93 $2.33 (17%)

Eliminate asset impairments and

restructuring charges associated with

previously announced manufacturing

decisions .08 -

Eliminate charge for a reduction in

expected insurance recoveries .06 -

Eliminate in-process research &

development charges associated with

ICOS, Hypnion, and Ivy acquisitions

and OSI in-licensing .58 -

Include pro forma as if the ICOS

acquisiti
'/>"/>